One of the most important sectors in any country’s economy is the biotech sector. Picking under-the-radar biotech stocks is easier said than done because we do not see immediate results. These companies have to move past the clinical trials and then prove that their drug or treatment is effective and safe.There are times when many of these candidates hit a dead wall, and the investment and research both go in vain. But if the company proves its worth, the rewards will be significant. This is why it takes a ...

Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have raised their dividends every one of the previous 25 straight years.Dividend growers had 11.7% compound annual returns from 1986 to 2016, while dividend payers had 9.9%. Dividend stocks are more resilient, so this outperformance is even greater during market volatility. This is great, since the markets are stil ...

These reliable dividend payers are no-brainer buys right now.It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago.A buoyant stock market makes it harder to find compelling investment opportunities, but not if you know where to look. With artificial intelligence-related businesses absorbing most investors ...

文章核心观点 - AbbVie的药物Tepkinly(epcoritamab)获得欧洲药品管理局(EMA)的CHMP委员会的正面意见,建议批准其用于治疗复发/难治性滤泡性淋巴瘤(R/R FL)的扩展适应症[1][2][6] - 如果获批,Tepkinly将成为欧盟首个获批用于治疗R/R FL和R/R DLBCL的双特异性抗体单药疗法[4] - AbbVie与Genmab合作开发Epkinly/Tepkinly,双方在美国和日本分担商业责任,AbbVie负责全球商业化[7][8] - AbbVie在2024年第一季度从Epkinly和Tepkinly的收益中获得2700万美元[9] - AbbVie和Genmab正在评估Epkinly作为单药和联合用药在多种血液肿瘤适应症中的疗效[10] 行业相关 - 滤泡性淋巴瘤(FL)是最常见的一种慢性非霍奇金淋巴瘤,而弥漫大B细胞淋巴瘤(DLBCL)是最常见的一种急性非霍奇金淋巴瘤[5] - 默克公司的肺动脉高压药物Winrevair获得CHMP的正面意见,有望成为欧洲首个激活素信号抑制剂疗法[11] - 强生公司的Balversa获得CHMP的正面意见,用于治疗FGFR基因改变的晚期或转移性膀胱癌[12]

As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael Joins AbbVie Board of DirectorsNORTH CHICAGO, Ill., July 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that Robert A. Michael has assumed the role of chief executive officer (CEO) and has joined AbbVie's Board of Directors, effective today. As previously announced, Mr. Michael succeeds Richard A. Gonzalez, who has served as CEO since the company's inception in 2013. Mr. ...

These stocks could be ideal for investors in their golden years.Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.Three Motley Fool contributors think they've found magnificent stocks retirees can buy and hold forever. Here's why they picked AbbVie (ABBV 1.50%), Gilead Sciences (GILD -0.32%), and Johnson & Johnson (JNJ 0.25%).A Dividend King poised for growthKeith Speight ...

AbbVie (ABBV) announced that it has acquired Celsius Therapeutics, a private biotech making novel therapies for treating inflammatory bowel diseases (“IBD”).The acquisition will add Celsius Therapeutics’ lead pipeline candidate, CEL383, to AbbVie’s pipeline. CEL383 is a potential first-in-class TREM1 inhibitor, which has completed phase I study in IBD conditions. AbbVie will pursue further development of CEL383.TREM1 has been identified as a key gene involved in inflammation pathways associated with IBD. In ...

If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyPositive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyNORTH CHICAGO, Ill., June 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) ...

AbbVie (ABBV) announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular lymphoma (FL). The drug has been developed in partnership with Genmab (GMAB) .The FDA approved Epkinlyunder the accelerated pathway to treat adults with relapsed or refractory (R/R) FL after two or more lines of therapies. The agency initially granted accelerated approval to the drug last year to treat patients with R/R diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphom ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned +10.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 5.2% over this period. Now the key question is: Where could the stock be headed in the near term?Although ...